L-arginine--substrate for no synthesis--its beneficial effects in therapy of patients with peripheral arterial disease: comparison with placebo-preliminary results.
Intravenous infusions of L-arginine (L-ARG) and placebo (saline) resulted in improvement of clinical assessments, statistically significant after L-ARG but not after saline. Results of laboratory estimations for platelet and fibrynolysis changed significantly following L-ARG infusions but not after infusions of placebo. These data indicate beneficial effects of L-ARG as a therapeutic agent in patients with peripheral arterial obliterative disease (PAOD). In these patients exogenous L-ARG can be converted to NO.
Slawinski
M
M
Grodzinska
L
L
Kostka-Trabka
E
E
Bieron
K
K
Goszcz
A
A
Gryglewski
R J
RJ
D000328:Adult; D000368:Aged; D001120:Arginine / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy / Q000473:pathology; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000502:physiology; D005080:Exercise Test; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009126:Muscle Relaxation / Q000187:drug effects; D019001:Nitric Oxide Synthase / Q000378:metabolism*
D001120:Arginine; D019001:Nitric Oxide Synthase